Advances in Oncolytic Immunotherapy

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across oncolytic immunotherapy. Next generation oncoloytic viral therapies, reovirus platforms, and cancer management strategies are depicted. The corresponding clinical trials scenario is illustrated, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics techno

Table of Contents

Advances in Oncolytic ImmunotherapyInnovations in Oncolytic ImmunotherapyNext-generation Oncolytic Viral Company Announces Senior Leadership AppointmentLeveraging Coxsackievirus for Oncolytic ImmunotherapyNovel Reovirus Platform for Cancer ManagementPsiOxus Therapeutics to Receive Milestone Payment from Bristol-Myers Squibb Clinical Trial Analysis and Industry InteractionsClinical Pipeline for ViralyticsSummary of Key Contacts

Related Research

Release Date : 21-Nov-18

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.